Manifestations, complications, and treatment of Neurobrucellosis: a systematic review and meta-analysis

doi:10.21203/rs.3.rs-1424537/v1

Purpose

Central nervous system involvement by Brucella species is the most morbid form of brucellosis disease. Studies on neurobrucellosis are scarce and limited to case reports and series. Brucella is unable to infect or harm neurons without the assistance of monocytes. This raises the question of whether ceftriaxone-based regimens are effective.

Methods

The primary aim of this study was to identify, evaluate, and summarize the findings of all relevant individual studies in the past 30 years to help better understand the disease. To achieve this, a broad systematic search was undertaken to identify all relevant records. Epidemiological and clinical features of the disease were assessed by the pooled analysis of descriptive studies. Through a meta-analysis, the treatment period duration was compared between the ceftriaxone-based and oral regimens using Standardized mean differences to measure effect size.

Results

448 patients were included in the Meta-analyses from 5 studies. A moderate positive effect was found for ceftriaxone-based regimens over oral treatments, and there was a significant difference between these two groups (SMD 0.428, 95% CI -0.63 to -0.22, I 2 = 37.64). Neurobrucellosis has a different clinical picture in pediatric patients. The disease is less chronic in children. Fever, nausea and vomiting, fatigue, and abdominal pain were significantly more prevalent symptoms in children, and Convulsions, ascites, sensorineural hearing loss, and papilledema were significantly more prevalent signs in children than adults.

Conclusion

It is recommended to initiate the treatment of neurobrucellosis with at least 14 days of IV ceftriaxone therapy in combination with oral therapy.

Neurobrucellosis

Meningitis

Ceftriaxone

Treatment

Children

Brucellosis is a common zoonosis with minimal mortality [1]. However brucellosis has a worldwide incidence, it is endemic in many parts of the world, including the Middle East and the Mediterranean basin [1, 2]. Central nervous system (CNS) involvement by Brucella species is uncommon and occurs in less than 5% of brucellosis patients [3]. Neurobrucellosis is a morbid form of brucellosis disease, presents with inflammatory signs and symptoms [4]. Although neurobrucellosis could present with various neurological syndromes, the major clinical picture is consistent with meningitis or meningoencephalitis presentation [5, 6]. Brucella enters the CNS using the Trojan horse mechanism mediated by brucella-infected monocytes to traverse the blood-brain barrier (BBB) and gain access to the brain parenchyma [7]. Brucella-infected monocytes also serve as a source of de novo infection for other cell types such as microglia and astrocytes [7].

Recent experimental findings elucidate that Brucella infection causes deregulation of astrocytes and microglia that creates a microenvironment in the CNS in which secretion of pro-inflammatory mediators leads to destabilization of the glial structure, the damage of the BBB, and neuronal loss [4]. The use of parenteral ceftriaxone as an initial component of therapy followed by long-term sequential oral antibiotics seems to reduce the course of the treatment and is effective in the management of the disease [6]. Due to the rare nature of the disease, it is not feasible to conduct clinical studies with an appropriate sample size, and data in the Literature are generally restricted to descriptive or retrospective studies [6, 8–11].

Thus this study aimed to identify, evaluate, and summarize the findings of all relevant individual studies to help better understand the course of the disease and raise the knowledge about both epidemiologic and clinical aspects of the disease.

This systematic review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [12], and a PRISMA checklist was completed. This systematic review was registered in PROSPERO (CRD42020167761).

Search strategy

A systematic search of literature published between January 1, 1990, and November 25, 2021, was conducted in the following electronic databases: MEDLINE, Web of Science, Scopus, and Cochrane Library. Terms referring to Brucellosis were combined with terms referring to CNS involvement (using both MeSH terms and text words) and we also checked the references of four narrative reviews on neurobrucellosis to supplement our searching [13–16]. Details of the searches and exact search strings are provided in the supplementary data. All the identified records were pooled and duplicate records removed before screening using Endnote X9 citation manager software. Then titles and abstracts were appraised by two independent screeners and irrelevant records were excluded. The full text of potentially relevant papers was retrieved if possible. The full text was independently reviewed by two authors (A.T. and M.S.) and any disagreements were discussed to reach a consensus.

Selection criteria

The patients were included in the study was merely among those who had consistent clinical findings of brucellosis and a serum agglutinin titer of ≥ 1:160 in serum tube agglutination (STA) or a positive blood culture who had symptoms and signs of neurological disease not otherwise explainable concomitant with the presence of any one of the following criteria: (1) isolation of Brucella species from cerebrospinal fluid (CSF); (2) positive enzyme-linked immunosorbent assay (ELYSA) or tube agglutination with coombs test using a cutoff ≥ 1:8 for Brucella antibodies in CSF; (3) presence of inflammatory alteration of CSF including lymphocytosis, increased protein and decreased glucose levels; (4) findings in cranial magnetic resonance imaging (MRI) or computed tomography (CT) scan in favor of neurobrucellosis. Hence there is no consensus on diagnostic antibody titer in CSF for neurobrucellosis, we set the cutoff ≥ 1:8 as it is highly sensitive and specific [17].

Only patients were included that were followed for a minimum of 3 months after they stopped antibiotic treatment and their final status was clearly mentioned. There was no restriction on the severity of symptoms or complications, no restriction on sample size, and both published and unpublished studies were included. Only studies published in English were eligible for inclusion.

Epidemiological features of the disease were assessed by the pooled analysis of descriptive studies. Pooled analyses can only be conducted if the included studies used the same study design [18] therefore we only included studies for the pooled analysis in which the full course of the disease and outcome was well-defined for each patient. Relative therapeutic effects of different classes of antibiotics were assessed by the Meta-analysis on retrospective studies.

Data extraction

For data extraction, two authors (A.T. and M.S.) independently reviewed all eligible articles and extracted the following data using electronic forms designed exclusively for extraction of data from descriptive studies by Oracle Database 10g and Oracle Forms 6i. Basic demographic data and details of signs and symptoms, laboratory findings, complications, radiologic findings, and the treatment interventions effect, were collected through data extraction. Conflicts were resolved by group consensus, with M.S. making the final decision for inclusion.

Assessment of risk of bias

The Joanna Briggs Institute (JBI) Critical Appraisal Checklist for Case Reports [19] was used for critical appraisal of each case included in the pooled analysis. JBI Critical appraisal tools have been developed by the JBI and collaborators and approved by the JBI Scientific Committee following extensive peer review [19]. The purpose of this tool is to assess the methodological quality of the study and address the possibility of bias in its design. The GRACE checklist [20] was used for the critical appraisal of retrospective studies included in the Meta-analysis. The risk of bias was assessed by two independent reviewers (A.T. and M.S.) and any disagreements were resolved by group consensus.

Data synthesis and statistical analysis

The primary outcome in the Meta-analysis was to compare the treatment period duration between ceftriaxone-based regimens and oral treatment. The effect size was measured by both standardized mean difference (SMD) and Hedges’ g which is a corrected effect size that tells you how much one intervention group differs from another [21]. Heterogeneity across the included studies for the Meta-analysis was evaluated using the I² statistic values, which describes the percentage of variation across studies that is due to heterogeneity rather than chance [21]. Heterogeneity is considered substantial when I² > 50%. Because the heterogeneity statistic I² can be biased in small Meta-analyses, we analyzed data using both fixed effect and random effect models [22].

Publication bias was subjectively assessed using funnel plots of precision for asymmetry and the classic fail-safe N test was conducted to assess the risk of publication bias quantitatively. All the analyses for this part were done using the Comprehensive Meta-Analysis (CMA) Software [23].

To synthesize data for pooled analyses of 274 neurobrucellosis cases extracted from descriptive articles, descriptive statistics were used to summarize the characteristics of the data set and were presented as frequencies, percentages for categorical variables, and mean ± standard deviation and median (min-max) for continuous variables. The chi-square test was used to compare the categorical variables. The Shapiro-Wilk test was used to evaluate the distribution of variables, and then the independent-samples T-test and the Mann-Whitney U test were used for the comparisons of continuous variables based on the results of the tests for normality. In the assessment of the relations between the variables, Pearson or Spearman correlation coefficients were calculated based on variable types. A P-value of less than 0.05 was considered to be statistically significant. Statistical analysis was conducted using IBM SPSS statistics 22 (IBM Corp., Armonk, NY, USA) to synthesize data for the pooled analyses.

As depicted in Fig. 1, 2784 records were identified by applying search strategy. After screening for duplicates and irrelevant studies, 448 records were sought for retrieval, and finally, after applying inclusion criteria, 142 studies were included for pooled analysis including 274 cases, and 4 studies were included for the Meta-analysis through electronic searches plus the pooled analysis of the therapeutic effects of ceftriaxone-based regimens conducted in this study, finally, 5 studies entered the Meta-analysis including 448 cases. The risk of bias for these articles is reported in Supplementary data, Table 1.

Epidemiologic characteristics

Extracting the data from 142 studies, resulted in finding 274 neurobrucellosis cases, meeting the inclusion criteria. 161 males and 113 females enrolled (M/F, 1.4:1). The mean age of neurobrucellosis patients was 31 ± 17.82, median = 29(0 to 82). Two maternal transmissions were reported in infants [24–26]. Patients were categorized into two age groups: 41 pediatric patients were defined by age ≤ 12 years and 233 adolescent and adult patients were defined by age > 12 years, and the rationale behind this classification was the different therapeutic protocols in this age group because of the doxycycline side effects in children.

To compare the onset of disease between age groups, the duration of symptoms was tested for normality, and the null hypothesis for normal distribution was rejected (p ≤ .001). Log-normal distribution of the onset of disease was suspected by examining quantile-quantile plots, therefore LN (onset of disease) was tested for normality, and failed to reject the null hypothesis for normal distribution (p = .095). It seems neurobrucellosis has log-normal distribution for the duration of symptoms (see supplementary data, Fig. 2). The mean duration of symptoms for pediatric patients was 73.34 ± 111.96, median = 30(2 to 430) days from onset of symptoms, and the mean duration of symptoms for adults was 121.87 ± 165.20, median = 60(1 to 850), and the distributions in the two groups differed significantly (Mann–Whitney U = 1574, N_P=32, N_A =144, P = 0.005). The Mood’s median test was also rejected for the assumption of the same medians between two age groups for the onset of disease (p = 0.013), (see Fig. 3). The frequency table for the nationality of all included cases is provided in Supplementary data, Table 2.

Table 2

Table 2 The frequency table for the nationality

	Frequency	Percent	Cumulative Percent
Turkey	126	46.0	46.0
Saudi Arabia	61	22.3	68.2
India	20	7.3	75.5
Iran	15	5.5	81.0
Tunisia	9	3.3	84.3
Italy	6	2.2	86.5
Israel	5	1.8	88.3
china	4	1.5	89.8
Spain	4	1.5	91.2
Lebanon	3	1.1	92.3
Portugal	3	1.1	93.4
USA	3	1.1	94.5
Greece	2	.7	95.3
Kuwait	2	.7	96.0
Argentina	1	.4	96.4
Bangladesh	1	.4	96.7
Bosnia	1	.4	97.1
Egypt	1	.4	97.4
Germany	1	.4	97.8
Korea	1	.4	98.2
Mexico	1	.4	98.5
Norway	1	.4	98.9
Pakistan	1	.4	99.3
Qatar	1	.4	99.6
UAE	1	.4	100.0
Total	274	100.0

Signs and Symptoms

The most common presenting symptoms and signs are shown in Table 3 and Table 4. For the comparison of signs and symptoms between pediatrics and adults, the chi-square test was used to determine whether the difference is meaningful. Fever (62.8%), headache (56.6%), nausea or vomiting (30.3), Muscular weakness (24.8%), and auditory impairment (21.2%) were consecutively the most common presenting symptoms. There was a significant difference in the prevalence of fever (p = 0.001), nausea or vomiting (p < 0.001), auditory impairment (p = 0.001), sensory loss (p = 0.017), fatigue (p < 0.001), and abdominal pain (p < 0.001) between age groups. Meningeal irritation signs (29.6%), Confusion (23.0%), Decreased muscle strength (14.2%), sensorineural hearing loss (13.5%), and increased DTR (8.8%) were consecutively the most common physical findings in this study. Convulsions (p = 0.001), Ascites (p < 0.001), Sensorineural hearing loss (p = 0.016), and papilledema (p = 0.002) have significant difference between age groups.

Table 3

Neurobrucellosis symptoms
symptoms	Pediatrics (n = 41)	Adults (n = 233)	P
fever	(n = 35)85.4	(n = 137)58.8	0.001
headache	(n = 24)58.5	(n = 131)56.2	0.783
nausea or vomiting	(n = 24)58.5	(n = 59)25.3	0.000
Muscular weakness	(n = 8)19.5	(n = 60)25.8	0.394
auditory impairment	(n = 1)2.4	(n = 57)24.5	0.001
walking difficulty	(n = 6)14.6	(n = 51)21.9	0.291
visual impairment	(n = 4)9.8	(n = 31)13.3	0.530
back pain	(n = 3)7.3	(n = 30)12.9	0.313
Joint pain	(n = 7)17.1	(n = 22)9.4	0.143
sensory loss	(n = 0)0.0	(n = 29)12.4	0.017
weight loss	(n = 5)12.2	(n = 22)9.4	0.585
Anorexia	(n = 5)12.2	(n = 19)8.2	0.399
sweating	(n = 2)4.9	(n = 22) 9.4	0.340
psychiatric	(n = 3)7.3	(n = 20)8.6	0.787
urinary incontinence	(n = 3)7.3	(n = 22)9.4	0.663
Malaise or fatigue	(n = 8)19.5	(n = 8)3.4	0.000
Dizziness	(n = 0)0.0	(n = 13)5.6	0.121
myalgia	(n = 1)2.4	(n = 11)4.7	0.510
chills	(n = 1)2.4	(n = 6)2.6	0.959
Abdominal pain	(n = 4)9.8	(n = 2)0.9	0.000
fecal incontinence	(n = 1)2.4	(n = 3)1.3	0.571

Table 4

Neurobrucellosis Signs
Signs	Pediatrics (n = 41)	Adults (n = 213)	p
Decreased muscle strength	(n = 7)17.1	(n = 32)15.0	0.739
Decreased DTR	(n = 2)4.9	(n = 22)10.3	0.275
Increased DTR	(n = 8)19.5	(n = 23)10.8	0.119
Meningeal irritation signs	(n = 15)36.6	(n = 66)31.0	0.481
Confusion	(n = 14)34.1	(n = 49)23.0	0.130
Hepatosplenomegaly	(n = 4)9.8	(n = 7)3.3	0.062
Hypoesthesia	(n = 0)0	(n = 10)4.7	0.157
Convulsions	(n = 11)26.8	(n = 18)8.5	0.001
Hemiparesis	(n = 2)4.9	(n = 26)12.2	0.170
Paraplegia	(n = 0)0	(n = 7)3.3	0.239
Dysarthria	(n = 0)0	(n = 17)6.1	0.104
Aphasia	(n = 2)4.9	(n = 13)6.1	0.761
Diplopia	(n = 3)7.3	(n = 23)10.8	0.501
Papilledema	(n = 12)29.3	(n = 24)11.3	0.002
Ataxia	(n = 5)12.2	(n = 30)14.1	0.748
positive Babinski sign	(n = 3)7.3	(n = 18)8.5	0.809
Ascites	(n = 3)7.3	(n = 0)0	0.000
Sensorineural hearing loss	(n = 1)2.4	(n = 36)16.9	0.016
Paraparesis	(n = 1)2.4	(n = 21)9.9	0.122
Tremor	(n = 1)2.4	(n = 9)4.2	0.590
Nystagmus	(n = 1)2.4	(n = 4)1.9	0.813
Positive Romberg's test	(n = 1)2.4	(n = 4)1.9	0.813
Decreased visual acuity	(n = 1)2.4	(n = 4)1.9	0.813

Laboratory findings

195 of 274 (71%) included cases had examined for CSF agglutination test which 179 (92%) of these cases had CSF titer ≥ 1:8. Among 95 cases with negative titer or no CSF agglutination assessment, 39 cases had positive CSF culture and 62 cases had inflammatory alteration of CSF including lymphocytosis and increased protein and decreased glucose levels, and 58 cases had positive MRI findings in favor of neurobrucellosis. CSF parameters descriptive statistics are summarized in Table 5.

91.8% of cases had CSF protein level > 45 mg/dl, and 62.1% cases had CSF glucose level < 40 mg/dl, and 88.0% of cases had CSF leukocyte count > 10 cells, and 92.8% of cases had CSF lymphocytic predominance > 50%.The correlations between different CSF parameters are summarized in Table 6 (Before the analysis of titration data, logarithmic transformation was performed based on log10). The frequency table of CSF titration is provided in Supplementary data, Table 7. CSF culture was done in 162 of 274 (59%) included cases and only 62 (38%) of these cultures were positive for Brucella species.

Table 5

CSF laboratory
	N	Mean ± SD	Median	IQR
Glucose	203	35.97 ± 15.950	34	19
Protein	244	184.60 ± 160.707	129.50	161
WBC	234	159.50 ± 148.581	107	200
Lymph	138	142.84 ± 103.712	119.47	122

Table 6

CSF parameters correlations
	CSF leukocyte counts	CSF glucose levels	CSF protein levels
Log10 CSF STA titer	r=-0.006 p = 0.936	r=-0.103 p = 0.222	r = 0.347 p = 0.000
CSF protein levels	r = 0.264 p = 0.000	r=-0.178 p = 0.013
CSF glucose levels	r=-0.172 p = 0.019

Radiologic findings

This study enrolled 274 neurobrucellosis patients, of whom 210 (76.6%) underwent cranial imaging. The cranial imaging of these 210 cases was categorized based on the classification suggested by the Istanbul‑3 study [27]. The data from radiological findings were categorized into 5 following subgroups: (1) In this study, 59 (28.1%) of 210 patients had normal cranial imaging. (2) inflammatory findings were categorized into 2 subgroups: (a) Diffuse inflammation including Leptomeningeal involvement (n = 44), and basal meningeal enhancement (n = 4). (B) Localized inflammation including cranial nerve involvement (n = 6), spinal nerve root enhancement (n = 14), CNS abscess (n = 18), granuloma (n = 16), and arachnoiditis (n = 3). (3) white-matter changes including Periventricular White matter Hyperintensities (PWMH, n = 24), Deep White matter hyperintensities (DWMH,n = 14), Leukoencephalopathy (n = 7), and Demyelinating plaque (n = 4), (4) 29 (13.8%) out of 210 patients had vascular involvement, and (5) There were 14 (6.7%) patients with hydrocephalus, and cerebral edema was seen in 5 (2.4%) out of 210 patients.

A comparison of radiologic findings between pediatrics and adults revealed that there is a significant difference in the prevalence of hydrocephalus (p < 0.001) and brain edema (p < 0.001) between age groups ( see Table 8).

Table 7 CSF titration frequency table

titers	Frequency	%	Cumulative %
<1:8	16	8.2	8.2
1:8	2	1.0	9.2
1:10	10	5.1	14.4
1:20	16	8.2	22.6
1:40	23	11.8	34.4
1:80	38	19.5	53.8
1:160	36	18.5	72.3
1:320	25	12.8	85.1
1:640	14	7.2	92.3
1:1280	10	5.1	97.4
>1:1280	5	2.6	100.0
Total	195	100

Table 8

Neurobrucellosis radiologic findings
Radiologic findings	Pediatrics (n = 23)	Adults (n = 187)	P
Normal imaging	(n = 6)26.1	(n = 53)28.3	0.820
Leptomeningeal enhancement	(n = 4)17.4	(n = 40)21.4	0.657
Basal meningeal enhancement	(n = 1)14.3	(n = 3)1.6	0.364
Spinal root enhancement	(n = 2)8.7	(n = 12)6.4	0.679
Cranial nerve enhancement	(n = 1)4.3	(n = 5)2.7	0.649
Abscess	(n = 5)21.7	(n = 13)7.0	0.017
Granuloma	(n = 0)0.0	(n = 16)8.6	0.144
Arachnoiditis	(n = 0)0.0	(n = 3)1.6	0.541
PWMH	(n = 0)0.0	(n = 24)12.8	0.068
DWMH	(n = 0)0.0	(n = 14)7.5	0.174
Leukoencephalopathy	(n = 0)0.0	(n = 7)3.7	0.345
Demyelinating plaque	(n = 0)0.0	(n = 4)2.1	0.479
Vascular involvement	(n = 1)4.3	(n = 28)15.0	0.163
Hydrocephalus	(n = 7)30.4	(n = 7)3.7	0.000
Edema	(n = 3)13.0	(n = 2)1.1	0.000

Complications and sequelae

The development of various complications during neurobrucellosis is presented in Table 9. Cranial nerve involvement (34.7%), upper motor neuron syndrome (17.9%), increased intracranial pressure (10.6%), radiculopathy (9.1%), and abscess formation (6.9%) were consecutively the most common complications. There was a significant difference in the prevalence of 8th cranial nerve involvement (p = 0.006), radiculopathy (p = 0.028), vp-shunt infection (p < 0.001), and hydrocephalus (p < 0.001) between age groups. Upper motor neuron syndrome refers to those neurobrucellosis patients presented with a combination of signs and symptoms including altered muscle tone, brisk tendon reflexes, positive Babinski reflex, and spastic paraparesis. On binary logistic regression, PWMH was associated with upper motor neuron syndrome (OR 3.15; 95% CI 1.29 to 7.69, p = 0.012). Sequela was defined as a chronic complication that remained even after completion of treatment at the 6th month of follow-up (see Table 10).

Table 9

Neurobrucellosis Complications
Complications	Pediatrics (n = 41)	Adults (n = 233)	P
Cranial nerve involvement II III V VI VII VIII X XI XII	(n = 9)22.0 (n = 4)9.8 (n = 1)2.1 (n = 0)0 (n = 2)4.9 (n = 2)4.9 (n = 2)4.9 (n = 0)0 (n = 0)0 (n = 0)0	(n = 86)36.9 (n = 14)6.0 (n = 5)2.1 (n = 3)1.3 (n = 22)9.4 (n = 11)4.7 (n = 56)24.0 (n = 2)0.9 (n = 2)0.9 (n = 3)1.3	0.063 0.372 0.906 0.465 0.340 0.965 0.006 0.552 0.553 0.465
Upper motor neuron	(n = 8)19.5	(n = 41)17.6	0.768
Increased intracranial pressure	(n = 5)12.2	(n = 24)10.3	0.716
Radiculopathy	(n = 0)0	(n = 25)10.7	0.028
CNS abscess	(n = 5)12.2	(n = 14)6.0	0.150
Hydrocephalus	(n = 7)17.1	(n = 6)2.6	0.000
Stroke	(n = 0)0	(n = 17)7.3	0.074
Peripheral neuropathy	(n = 0)0	(n = 12)5.2	0.137
CNS granulomas	(n = 0)0	(n = 9)3.9	0.201
Vp-shunt infection	(n = 7)17.1	(n = 2)0.9	0.000
Myelitis	(n = 0)0	(n = 8)3.4	0.229
Death	(n = 1)2.4	(n = 4)1.7	0.750
Sinus thrombosis	(n = 1)2.4	(n = 4)1.7	0.750
SIADH	(n = 0)0	(n = 2)0.9	0.552
DI	(n = 0)0	(n = 2)0.9	0.552
Subdural empyema	(n = 1)2.4	(n = 1)0.4	0.163
Mycotic aneurysm	(n = 0)0	(n = 2)0.9	0.552
Arachnoiditis	(n = 0)0	(n = 1)0.4	0.674
Vasculitis	(n = 0)0	(n = 1)0.4	0.674

Table 10

Neurobrucellosis squealae
squealae	%(N)
Sensorineural Hearing loss	15.0 (n = 38)
Decreased visual acuity	2.8 (n = 7)
Motor deficit	5.9 (n = 15)
Relapse	2.4 (n = 6)
Cognitive dysfunction	0.8 (n = 2)

Therapeutic failure

Therapeutic failure was defined as the lack of efficacy of the treatment, relapse, and death. 16 (5.8%) of 274 cases met the criteria for therapeutic failure. The characteristics, treatment courses, and outcomes of these cases are described in Table 11.

Table 11

Therapeutic failure
Age/Sex	onset(days)	imaging findings	CSF titer	CSF culture	CSF profile	Treatment regimen	Duration of treatment	Outcome
35/F	180	Pos.	1:160	-	Pos.	Ce/Ri/Do	-	Relapse
52/M	20	Pos.	1:80	-	Pos.	Ge/Ci/Do	2 Weeks	Death
29/M	-	Pos.	-	-	Pos.	Co/Ri/Do	18 Months	NCL
8/M	2	-	-	-	Pos.	-	1 DAY	Death
15/M	180	Neg.	1:160	-	Pos.	Co/Ri/Do	12 Months	NCL
59/M	150	Pos.	-	Neg.	Pos.	Ce/Ri/Do	2 Weeks	Death
65/M	390	Pos.	1:64	-	Neg.	Ge/Ri/Do	6 Months	Relapse
32/F	730	Pos.	1:80	Neg.	Pos.	Ce/Ri/Do	17 Months	NCL
35/F	90	Pos.	1:160	-	Pos.	Co/Ri/Do	9 Months	Relapse
40/M	30	Pos.	1:40	Neg.	Pos.	Ci/Ri/Do	3 Months	NCL
35/M	45	-	-	Pos.	Pos.	Co/Ri/Do	13 Months	Relapse
30/F	90	Pos.	-	-	-	Co/Ri	16 Weeks	Relapse
38/M	-	-	-	Pos.	Pos.	Ri/Do	12 Months	Relapse
24/M	365	-	-	Neg.	Pos.	St/Ri	7 Days	Death
9/M	14	-	-	Pos.	Neg.	Ce/Ri/Do	18 Months	NCL
68/F	-	Pos.	1:40	Neg.	Pos.	Ce/Ri/Do	2 Weeks	Death

Ce, Ceftriaxone; Ri, Rifampin; Do, Doxycycline; Ge, Gentamycin; Ci, Ciprofloxacin; St, Streptomycin

Treatment

The duration of the treatment period was compared between ceftriaxone-based regimens and oral treatment for each age group using an independent-sample T-test. The ceftriaxone-based regimen group was defined as patients receiving IV ceftriaxone, rifampin, doxycycline, and ± TMP/SMX, and the oral treatment group was defined as patients receiving rifampin, doxycycline, and ± TMP/SMX. Other patients receiving unconventional therapies like ciprofloxacin was excluded, therefore 34 pediatric patients and 206 adults were included. In adults, 113 patients receiving ceftriaxone-based regimens with the mean duration of 4.93 ± 2.72, median = 6(1 to 17), had treatment period significantly shorter than 93 patients receiving oral treatment with the mean duration of 6.08 ± 3.41, median = 6(1.5–20), and by the mean difference of -1.14(95% CI -1.99 to -0.3, p = 0.008) the null hypothesis is rejected.

In pediatric patients, 11 patients receiving ceftriaxone-based regimens with the mean duration of 6.45 ± 5.05, median = 6(1.5 to 18), had no significant difference in treatment period with 23 patients receiving oral treatment with the mean duration of 4.02 ± 2.04, median = 3(1.5 to 10), and by the mean difference of 2.43(95% CI -1.02 to 5.89, p = 0.151) failed to reject the null hypothesis. There was no meaningful difference in the treatment period between patients receiving less than one month of IV ceftriaxone and those receiving at least one month of IV ceftriaxone in adults, by the mean difference of -0.52 (95% CI -1.64 to 0.61, p = 0.361).

The relations between treatment period and patient characteristics were assessed by Pearson correlation coefficients for continuous variables and Spearman correlation coefficients for discrete variables, in order to find factors that prolong the treatment period, summary statistics are presented in Table 12. Duration of symptoms (r = 0.296, p = 0.028), CSF Protein levels (r = 0.227, p = 0.042), VIII CN involvement (r = 0.215, p = 0.039) upper motor neuron syndrome (r = 0.215, p = 0.038), and positive imaging (r = 0.322, p = 0.002) were correlated to prolonged treatment period in adults receiving oral therapy. These factors had no meaningful correlation with prolonged treatment periods in adults receiving ceftriaxone-based therapy.

Table 12

Treatment period correlations with patients’ characteristics

	Ceftriaxone-based	Oral
Duration of symptoms	r = 0.146 p = 0.127	r = 0.296 p = 0.028
CSF Protein levels	r = 0.186 p = 0.133	r = 0.227 p = 0.042
Log10 CSF STA titer	r = 0.194 p = 0.083	r = 0.040 p = 0.747
papilledema	r=-0.124 p = 0.190	r=-0.245 p = .018
VIII CN involvement	r = 0.161 p = 0.089	r = 0.215 p = 0.039
upper motor neuron syndrome	r = 0.139 p = 0.141	r = 0.215 p = 0.038
Positive imaging	r = 0.010 p = 0.920	r = 0.322 p = 0.002

Meta-analysis

The results of our meta-analyses are shown in Tables 13 and 14. The primary outcome in the Meta-analysis was to compare the treatment duration between ceftriaxone-based regimens and oral treatment. 4 retrospective studies were identified through database searching plus the pooled analysis from this study met the inclusion criteria to enter the Meta-analysis. 448 patients were included in this analysis. A moderate positive effect (SMD = 0.428, 95% CI -0.63 to -0.22, p < 0.001) was found for ceftriaxone-based regimens over oral treatment, and there was a significant difference between these 2 groups. Although heterogeneity was not substantial (I² = 37.64, p = 0.170), a random effect model was also considered because of bias in the heterogeneity of small Meta-analyses. The forest plots for both SMD and Hedges’ g measure of effect, are provided in supplementary data, Fig. 4 and Fig. 5.

Publication bias was subjectively assessed for asymmetry in the funnel plot of precision (see Fig. 6). The bottom of the plot (which smaller studies appear towards there) shows a higher concentration of studies on the right side of the effect size, this would reflect the fact that there is a publication bias in this study. The classic fail-safe N test was conducted to determine how many missing non-significant studies would nullify the observed effect if we locate and include them in the analysis. The fail-safe N is 4, this means we would need to locate and include 4 null studies so that the p-value exceeds 0.05 and therefore the observed effect becomes insignificant. This shows that the possibility of publication bias is considerable in this study.

Table 13

Meta-analysis, effect size: SMD
Study name	n	SMD (95% CI)	p-value
Pooled 2022	206	-0.37(-0.65to-0.10)	0.008
Erdem 2012	208	-0.66(-1.00to-0.32)	0.000
Asadipooya 2011	19	0.52(-0.38to1.44)	0.259
Gul 2008	10	0.00(-1.54to1.54)	1.000
Akdeniz 1998	5	-0.38(-2.19to1.41)	0.674
Fixed	448	-0.42(-0.63to-0.22)	0.000
Random	448	-0.36(-0.70to-0.03)	0.033

Table 14

Meta-analysis, effect size: Hedges’ g
Study name	n	Hedges’ g (95% CI)	p-value
Pooled 2022	206	-0.37(-0.65to-0.09)	0.008
Erdem 2012	208	-0.66(-1.00to-0.31)	0.000
Asadipooya 2011	19	0.50(-0.37to1.37)	0.259
Gul 2008	10	0.00(-1.40to1.40)	1.000
Akdeniz 1998	5	-0.28(-1.59to1.03)	0.674
Fixed	448	-0.41(-0.62to-0.21)	0.000
Random	448	-0.35(-0.68to-0.01)	0.040

CNS involvement by Brucella species is the most morbid form of brucellosis disease [4]. The inflammatory pathogenic mechanisms involved in damage to CNS have been recently elucidated by both in vivo and in vitro evidence [28]. The Trojan horse mechanism of Brucella traversing the BBB by Brucella-infected monocytes and then de nonvo infection of microglia and astrocytes has been described by Miraglia et al., 2018 [7]. In this study, 92.8% of cases had CSF lymphocytic predominance which is evidence that the integrity of the BBB is altered by neurobrucellosis since the infection of CNS activates the BBB and modifies its integrity, and is mediated by astrocytes and microglia with immune basis [28]. Brucella is recognized by glial cells throughout TLR2, NLRP3, and AIM2 which induces astrogliosis and BBB endothelial cells activation, so this leads to an increase in the permeability of BBB to monocytes and neutrophils [4, 29–31]. Brucella is unable to infect or harm primary cultures of mouse neurons However, when neurons were co-cultured with microglia, Brucella caused a significant neuronal loss [32]. This neuronal loss is not due to apoptosis, rather the microglial primary phagocytosis of live neurons causes neuronal death, since blocking microglial phagocytosis prevented neuronal loss without increasing the number of apoptotic neurons, thus phagocytosis was the cause of death and not its consequence [32].

Although it seems immune mediators play an important role in the pathophysiology of the disease, there is not enough evidence in favor or against the effect of steroids with regards to treating neurobrucellosis. In cases misdiagnosed as autoimmune diseases like SLE or MS, receiving methylprednisolone without any proper antibiotic therapy led to the progression of the disease after about one week of initial improvement of the symptoms, therefore we recommend avoiding the initiation of the corticosteroids before proper antibiotic therapy [33, 34].

81% of included patients were from Turkey, Saudi Arabia, India, and Iran which indicates although neurobrucellosis is rare, it is still an important health issue in these four countries and they need preventive health care programs to decrease the burden of the disease since the eradication of brucellosis in humans is only possible by the control of the disease in animals.

Neurobrucellosis has a different clinical picture in pediatric patients. The disease is less chronic in children, and the median of the course of the symptoms is 30 days shorter in this population. Fever, nausea and vomiting, fatigue, and abdominal pain were more prevalent in children. Also, convulsions, ascites, sensorineural hearing loss, and papilledema are more prevalent signs in children. One of the most important clinical pictures in children was ventriculoperitoneal shunt infection (17.1%), especially in patients with a history of hydrocephalus. This infection may lead to a peritoneal infection presented with abdominal pain. Removing VP-shunt was the key factor to treat these patients. Temporary placement of external ventricular drains could help patients with high intracranial pressure to complete the treatment course. After completion of the treatment and recovery, the VP-shunt could be placed again [35–40]. VIII CN involvement was significantly less common in children with only 2 cases observed.

In the assessment of the relations between treatment period and patients characteristics, there was a meaningful positive correlation (r) between treatment period and parameters like duration of symptoms, CSF protein levels, positive imaging, VIII CN involvement, and upper motor neuron syndrome in patients treated with oral antibiotics which means these parameters are correlated with a prolonged course of treatment. But the correlations between these parameters and treatment period were no longer meaningful in patients who received ceftriaxone-based regimens. This indicates that ceftriaxone-based regimens neutralize the effects of treatment prolonging factors and this is another evidence for the superiority of ceftriaxone-based regimens over oral treatments.

The results of the pooled analysis were in favor of 1.14 (95% CI 1.99 to 0.3) month shorter treatment period with ceftriaxone-based regimens in adults. There was no meaningful difference in the treatment period between patients receiving less than one month of IV ceftriaxone and those receiving at least one month of IV ceftriaxone, therefore it is recommended to initiate the treatment of neurobrucellosis with at least 14 days of IV ceftriaxone therapy in combination with oral therapy. The overall treatment period is dependent on the patient’s characteristics, especially CSF parameters but 6 months of treatment seems to be sufficient as a general recommendation, although the treatment should be continued until the normalization of CSF parameters. There was not enough data to conclude the superiority of any regimens in children and results were not meaningful.

The results of the meta-analyses also showed a moderate positive effect (SMD 0.428, 95% CI -0.63to-0.22) of ceftriaxone-based regimens in shortening the treatment period over oral therapy in adults.

Unfortunately, studies on neurobrucellosis are scarce and limited to case reports or series with limited cases. thus the risk of bias in this study is considerable and at least 4 more studies on the treatment of neurobrucellosis are needed to decrease the risk of publication bias. By the way, the summary of the past 32 years of research on neurobrucellosis favors the superiority of parenteral ceftriaxone treatment in combination with doxycycline and rifampin compared to oral regimens.

CSF

Cerebrospinal fluid

CNS

Central nervous system

BBB

blood-brain barrier

PRISMA

Preferred Reporting Items for Systematic Reviews and Meta-Analysis

JBI

Joanna Briggs Institute

CI

Confidence interval

RR

Risk ratio

I2

I-squared.

Conflict of Interest

None declared.

Acknowledgements

The present study was supported by Arak University of Medical Sciences, Arak, Iran, Islamic Republic Of.

Authors’ contributions

A.T. and M.S designed the study protocol and did the literature search, study quality assessment and data extraction by A.T. and M.S., and A.T. performed the statistical analysis and drafted the tables and figures. A.T. wrote the first draft of this analysis, N.Z. and A.R. helped to finish the final version. N.Z. and A.R. helped with revision of the manuscript. All authors approved the conclusions of our study.

Funding

The study supported by Infectious Diseases Research Center (IDRC), Arak University of medical sciences, Arak, Iran, Islamic Republic Of. ID: 6197.

Availability of data and materials

The datasets generated during and analysed during the current study are available in the Excel® repository, https://file.io/2mMudcJZEprG, Password: nb1234.

Ethics approval

This study is Evaluated by Research Ethics Committees of Arak University of Medical Sciences and Approved on 2020-08-02. Approval ID: IR.ARAKMU.REC.1399.167.

Franco MP, Mulder M, Gilman RH, Smits HL (2007) Human brucellosis. Lancet Infect Dis 7(12):775–786
Pappas G, Papadimitriou P, Akritidis N, Christou L, Tsianos EV (2006) The new global map of human brucellosis. Lancet Infect Dis 6(2):91–99
Buzgan T, Karahocagil MK, Irmak H, Baran AI, Karsen H, Evirgen O et al (2010) Clinical manifestations and complications in 1028 cases of brucellosis: a retrospective evaluation and review of the literature. Int J Infect Dis 14(6):e469–e478
Rodríguez AM, Delpino MV, Miraglia MC, Giambartolomei GH (2019) Immune Mediators of Pathology in Neurobrucellosis: From Blood to Central Nervous System. Neuroscience 410:264–273
Bashir R, Al-Kawi MZ, Harder EJ, Jinkins J (1985) Nervous system brucellosis: diagnosis and treatment. Neurology 35(11):1576–1581
Erdem H, Ulu-Kilic A, Kilic S, Karahocagil M, Shehata G, Eren-Tulek N et al (2012) Efficacy and tolerability of antibiotic combinations in neurobrucellosis: results of the Istanbul study. Antimicrob Agents Chemother 56(3):1523–1528
Miraglia MC, Rodriguez AM, Barrionuevo P, Rodriguez J, Kim KS, Dennis VA et al (2018) Brucella abortus Traverses Brain Microvascular Endothelial Cells Using Infected Monocytes as a Trojan Horse. Front Cell Infect Microbiol 8:200
Gul HC, Erdem H, Gorenek L, Ozdag MF, Kalpakci Y, Avci IY et al (2008) Management of neurobrucellosis: an assessment of 11 cases. Intern Med 47(11):995–1001
Haji-Abdolbagi M, Rasooli-Nejad M, Jafari S, Hasibi M, Soudbakhsh A (2008) Clinical and laboratory findings in neurobrucellosis: review of 31 cases. Arch Iran Med 11(1):21–25
Akdeniz H, Irmak H, Anlar O, Demiröz AP (1998) Central nervous system brucellosis: presentation, diagnosis and treatment. J Infect 36(3):297–301
Asadipooya K, Dehghanian A, Omrani GH, Abbasi F (2011) Short-course treatment in neurobrucellosis: a study in Iran. Neurol India 59(1):101–103
Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151(4):264–269w64
Gul HC, Erdem H, Bek S (2009) Overview of neurobrucellosis: a pooled analysis of 187 cases. Int J Infect Dis 13(6):e339–e343
Kizilkilic O, Calli C, Neurobrucellosis (2011) Neuroimaging Clin N Am 21(4):927–937 ix
Pappas G, Akritidis N, Christou L (2007) Treatment of neurobrucellosis: what is known and what remains to be answered. Expert Rev Anti Infect Ther 5(6):983–990
Patra S, Kalwaje Eshwara V, Pai AR, Varma M, Mukhopadhyay C (2021) Evaluation of clinical, diagnostic features and therapeutic outcome of neurobrucellosis: a case series and review of literature.Int J Neurosci. :1–11
Guven T, Ugurlu K, Ergonul O, Celikbas AK, Gok SE, Comoglu S et al (2013) Neurobrucellosis: clinical and diagnostic features. Clin Infect Dis 56(10):1407–1412
Blettner M, Sauerbrei W, Schlehofer B, Scheuchenpflug T, Friedenreich C (1999) Traditional reviews, meta-analyses and pooled analyses in epidemiology. Int J Epidemiol 28(1):1–9
Gagnier JJKG, Altman DG, Moher D, Sox H, Riley D, CARE Group (2013) The CARE Guidelines: Consensus-Based Clinical Case Reporting Guideline Development. Headache: The Journal of Head and Face Pain 53(10):1541–1547
Dreyer NA, Bryant A, Velentgas P (2016) The GRACE Checklist: A Validated Assessment Tool for High Quality Observational Studies of Comparative Effectiveness. J Manag Care Spec Pharm 22(10):1107–1113
Higgins JPTTJ, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (eds) (2019) Cochrane Handbook for Systematic Reviews of Interventions. John Wiley & Sons, Chichester (UK)
von Hippel PT (2015) The heterogeneity statistic I2 can be biased in small meta-analyses. BMC Med Res Methodol 15(1):35
Borenstein M, Hedges L, Higgins J, Rothstein H (2013) Biostat. Comprehensive Meta-Analysis Version 3. Englewood, NJ
Calik M, Iscan A, Gul M, Derme T, Cece H, Torun MF (2012) Severe neurobrucellosis in a young infant. Clin Neurol Neurosurg 114(7):1046–1048
Tikare NV, Mantur BG, Bidari LH (2008) Brucellar meningitis in an infant–evidence for human breast milk transmission. J Trop Pediatr 54(4):272–274
Dadar M, Shahali Y, Alamian S (2021) Isolation of Brucella melitensis biovar 1 from human milk confirms breastfeeding as a possible route for infant infection.Microb Pathog. ; 157
Erdem H, Senbayrak S, Meriç K, Batirel A, Karahocagil MK, Hasbun R et al (2016) Cranial imaging findings in neurobrucellosis: results of Istanbul-3 study. Infection 44(5):623–631
García Samartino C, Delpino MV, Pott Godoy C, Di Genaro MS, Pasquevich KA, Zwerdling A et al (2010) Brucella abortus Induces the Secretion of Proinflammatory Mediators from Glial Cells Leading to Astrocyte Apoptosis. Am J Pathol 176(3):1323–1338
Dong Y, Benveniste EN (2001) Immune function of astrocytes. Glia 36(2):180–190
Miraglia MC, Costa Franco MM, Rodriguez AM, Bellozi PM, Ferrari CC, Farias MI et al (2016) Glial Cell-Elicited Activation of Brain Microvasculature in Response to Brucella abortus Infection Requires ASC Inflammasome-Dependent IL-1β Production. J Immunol 196(9):3794–3805
Rosenzweig HL, Planck SR, Rosenbaum JT (2011) NLRs in immune privileged sites. Curr Opin Pharmacol 11(4):423–428
Rodríguez AM, Delpino MV, Miraglia MC, Costa Franco MM, Barrionuevo P, Dennis VA et al (2017) Brucella abortus-activated microglia induce neuronal death through primary phagocytosis. Glia 65(7):1137–1151
Bains R, Dahhan T, Belzowski A, Heinze ER, Wong AL, Clements PJ (2018) An Interesting Case of Neurobrucellosis Mimicking Neuropsychiatric Lupus. Case Rep Rheumatol 2018:9793535
Miyares FR, Deleu D, ElShafie SS, Equia F, Mesraoua B, Al Hail H et al (2007) Irreversible papillitis and ophthalmoparesis as a presenting manifestation of neurobrucellosis. Clin Neurol Neurosurg 109(5):439–441
Sudhamshu KC, Kumar AR, Dias M, Shubha AM, Das K (2016) Neurobrucellosis Infection of Ventriculoperitoneal Shunt Presenting as Peritonitis. Indian J Pediatr 83(9):1024
Al-Otaibi A, Almuneef M, Shaalan MA (2014) Brucella melitensis infection of ventriculo-peritoneal shunt: A form of neurobrucellosis manifested as gastrointestinal symptoms. J Infect Public Health 7(1):62–65
Abdinia B, Barzegar M, Malaki M, Behbod H, Oskoui S (2013) Association of Brucella meningoencephalitis with cerebrospinal fluid shunt in a child: a case report. Iran J Child Neurol 7(1):35–38
Locutura J, Lorenzo JF, Miján A, Galdós-Barroso M, Saez-Royuela F (1998) Non-simultaneous Brucella peritonitis and meningitis in a patient with a ventriculoperitoneal shunt. Eur J Clin Microbiol Infect Dis 17(5):361–362
Al-Qarhi R, Al-Dabbagh M (2021) Brucella Shunt Infection Complicated by Peritonitis: Case Report and Review of the Literature. Infect Dis Rep 13(2):367–376
Covrig RC, Petridou J, Knappe UJ (2021) Atypical Presentation of Neurobrucellosis as Infection of Ventriculoperitoneal Shunt. J Neurol Surg A Cent Eur Neurosurg 82(2):186–188

Table 1 is available in the Supplementary Files section.

Manifestations, complications, and treatment of Neurobrucellosis: a systematic review and meta-analysis

Status:

Version 1

Abstract

Purpose

Methods

Results

Conclusion

Figures

Introduction

Materials And Methods

Results

Discussion

Conclusion

Abbreviations

Declarations

References

Table 1

Supplementary Files

Status:

Version 1